How much VO2max do I lose if I stop training?
21 small athlete studies: about 4% after up to a month off and 9% after longer (authors' averages), no clear further fall past 90 days. Uncontrolled studies, reporting errors.
Zheng et al. searched Web of Science, SPORTDiscus, PubMed and Scopus (English, to 31 March 2021) for studies that reported VO2max in athletes before and after a defined period without training. Of 3315 records, 21 studies were included; breaks ran from 10 to 730 days. Each study's before-after change was expressed as a standardised mean difference (Hedges' g).
After 30 days or less, VO2max fell by SMD −0.62 (95% CI −0.94 to −0.31; I² 35.3%), and after longer breaks by SMD −1.42 (−1.99 to −0.84; I² about 77%); the long-term fall was larger (Q = 6.5, p = 0.01). Within long breaks, there was no evidence of a difference between 30-90 days and over 90 days (Q = 0.54, p = 0.46).
In long breaks the loss was larger in athletes training at least 5 times a week before the break and with complete rather than partial cessation, and borderline larger in under-20s (three studies, p = 0.05, CI crossing zero); in short breaks there was no evidence of a difference for any of these moderators.
The authors translate the pooled effects into average falls of 3.93% (short) and 9.43% (long) without saying how, and conclude that athletes should keep doing some exercise during a break.
Our reading: the direction and the levelling-off agree with REF-1133, REF-377 and REF-374; the magnitudes are rough, and the paper's errors (see Key Results) mean its subgroup findings should not carry weight on their own.
Protocol
Key Results
| Comparison | k | SMD (95% CI) | Heterogeneity |
|---|---|---|---|
| Short-term, 30 days or less | 14 (Table 4) | −0.62 (−0.94 to −0.31) | I² 35.3%; Egger p = 0.335 |
| Long-term, over 30 days | not stated | −1.42 (−1.99 to −0.84) | I² 76.3% (abstract) or 77% (Results); Egger p < 0.01 |
| Short vs long | — | Q = 6.5, p = 0.01 | — |
| Long: 30-90 days / over 90 days | 12 / 7 | −1.6 (−2.47 to −0.74) / −1.20 (−2.13 to −0.28) | Q = 0.54, p = 0.46 |
| Long: higher / lower training status | 10 / 4 | −1.91 (−2.57 to −1.25) / −0.85 (−1.83 to 0.12) | Q = 4.24, p = 0.03 |
| Long: under 20 / 20 and over | 3 / 16 | −2.81 (−6.32 to 0.69) / −1.20 (−1.76 to −0.64) | Q = 5.9, p = 0.05 |
| Long: complete / partial cessation | 16 / 4 | −1.69 (−2.41 to −0.96) / −0.65 (−1.42 to 0.11) | Q = 6.23, p = 0.01 |
| Short: higher / lower training status | 7 / 7 | −0.76 (−1.10 to −0.41) / −0.46 (−0.75 to −0.18) | Q = 1.45, p = 0.22 |
| Short: complete / partial cessation | 11 / 3 | −0.54 (−0.82 to −0.26) / −0.65 (−1.00 to −0.30) | Q = 0.36, p = 0.55 |
Mechanisms
Practical Application
Limitations
How this entry was checked and changed
read from the full text (Europe PMC, open access, CC BY 4.0). The rubric's A- line is an SR/MA with serious heterogeneity or mostly small trials; graded one step lower because the inputs are not trials but small uncontrolled before-and-after studies (sample sizes 5 to 67), quality was scored with a reporting checklist (STROBE) rather than a risk-of-bias tool, repeated time points from the same athletes enter as separate comparisons, the long-term pool shows small-study bias (Egger p < 0.01), and the report has internal errors (subgroup confidence intervals that cross zero are given p < 0.001; the quality table labels studies inconsistently and one label matches no reference; one study appears to be cited to the wrong reference). It sits at the same level as REF-1133, which reviews many of the same primary studies without pooling